Eli Lilly to lead oligonucleotide therapy development in new collaboration

**Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies Using AI Technology**

Eli Lilly and Company has announced a collaboration with Creyon Bio aimed at advancing the development of RNA-targeted oligonucleotide therapies. The partnership will leverage artificial intelligence (AI) technology to enhance the safety and efficacy of these treatments, which are designed to target specific RNA sequences within cells.

The collaboration seeks to address challenges in oligonucleotide therapy development by utilizing AI-driven approaches to optimize drug design and delivery. Oligonucleotides, short strands of nucleic acids, have shown promise in treating various diseases by modulating gene expression or targeting disease-causing RNA molecules. By integrating AI into the process, Eli Lilly and Creyon Bio aim to improve precision in targeting RNA while minimizing potential side effects. This initiative reflects ongoing efforts within the pharmaceutical industry to harness advanced technologies for innovative therapeutic solutions.

Newsflash | Powered by GeneOnline AI

Source: https://www.europeanpharmaceuticalreview.com/news/254766/eli-lilly-to-lead-oligonucleotide-therapy-development-in-new-collaboration/

Related posts:

Data Clean Rooms Revolutionize Secure Healthcare Data Sharing A protein link between brain diseases and leaky blood vessels Study Links Over Six Hours of Daily Screen Time to a 15% Reduction in Attention Span in Young Adults. Express Pharma’s May 2025 Issue Highlights Global Expansion of Indian Pharma & Biotech

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後